CD274 and neoplasm: Currently, emerging primary biomarkers used in response to immunotherapy are PD-1/PD-L1 protein expression, microsatellite instability (MSI), and tumor mutational burden (TMB) (Topalian et al., 2016; Chalmers et al., 2017; Chang et al., 2017).